If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

  • This share is currently suspended. It was suspended at a price of 43.10
  • There is currently no data for LABS

Rolling Stock Yard fully let

27 Jun 2025 07:00

RNS Number : 6386O
Life Science REIT PLC
27 June 2025
Β 

27 June 2025

LEI: 213800RG7JNX7K8F7525

Life Science REIT plc

("Life Science REIT" or the "Company")

Rolling Stock Yard fully let, with Wayve Technologies taking the remaining two floors

Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life sciences properties, has let 10,500 sq ft of space at its Rolling Stock Yard asset, located in London's Knowledge Quarter, to Wayve Technologies Ltd ("Wayve"), a pioneer in Embodied AI for automotive and a leader in AI in the UK.

Wayve has signed a lease for just over five years, with a break in November 2028, for floors seven and eight, and are paying a rent of Β£84.50 psf. The transaction follows the vacation of Xero Limited, just three months ago. As a result, Rolling Stock Yard is now fully let.

Ian Harris, Director of Asset Management at Ironstone Asset Management, the Company's Investment Adviser, said: "As a pioneer in AI and leader in the field of automated driving, Wayve is a perfect fit for the portfolio, and we are delighted to welcome them to Rolling Stock Yard. The speed with which we have re-let this remaining space is a testament to the quality of the building, the strength of its location, and the resilience of demand for space of this size."

Wayve was founded in 2017 and in May 2024, it announced a +$1 billion series C investment round, led by SoftBank Group, with contributions from NVIDIA, Microsoft and Uber.Β 

Rolling Stock Yard was acquired by Life Science REIT in December 2021. It is a premium, nine-storey building near St Pancras station in London, covering 53,900 sq ft.

Β 

END

Β 

Enquiries:

Ironstone Asset Management - Investment Adviser

Β +44 20 3011 2160

Simon Farnsworth, Managing Director

Simon.farnsworth@ironstoneam.com

Joanna Waddingham, Head of Investor Relations and Corporate Affairs

Joanna.Waddingham@ironstoneam.com

Β 

Β 

Link Company Matters Limited - Company Secretary

Β 

labs_cosec@linkgroup.co.uk

Β 

Β 

Β 

Panmure Liberum Limited - Corporate Broker and Financial Adviser

+44 20 3100 2000

Alex Collins / Tom Scrivens

Β 

Β 

G10 Capital Limited - AIFM

+44 20 7397 5450

Maria Baldwin

Β 

FTI Consulting - Financial PR

Β 

+44 20 3727 1000

Dido Laurimore / Richard Gotla / Oliver Parsons

LifeScienceReit@fticonsulting.com

Β 

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is underpinned by strong structural drivers, including an ageing population and a supportive regulatory environment as well as the growing interdependence with technology, which is expanding the life science spectrum, driving strong demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available atΒ https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCQQLFLEQLFBBX
Date   Source Headline
29th Jan 202612:19 pmRNSForm 8.3 - British Land Co PLC, The
29th Jan 202612:13 pmRNSForm 8.3 - Life Science REIT PLC
29th Jan 202611:58 amRNSForm 8.5 (EPT/RI)- Life Science REIT plc
29th Jan 202611:49 amRNSForm 8.3 Life Science REIT Plc
29th Jan 202611:39 amRNSForm 8.5 (EPT/RI)
29th Jan 202610:09 amRNSForm 8.5 (EPT/RI)-Life Science REIT plc
29th Jan 202610:06 amRNSForm 8.3
29th Jan 202610:02 amRNSForm 8.5 (EPT/NON-RI)-Life Science REIT plc
28th Jan 20262:54 pmRNSForm 8.3 - Life Science REIT plc
28th Jan 20262:19 pmRNSForm 8.3 - Life Science REIT Plc
28th Jan 20261:55 pmRNSForm 8.3 - British Land Company plc, The
28th Jan 20261:52 pmRNSForm 8.3 - Life Science REIT plc
28th Jan 202611:47 amRNSForm 8.3 - Life Science REIT plc
28th Jan 202610:22 amRNSForm 8.3 - Life Science REIT plc
28th Jan 20267:50 amRNSDisclosure Table
28th Jan 20267:00 amRNSRecommended offer for Life Science REIT PLC
27th Jan 20262:39 pmRNSHolding(s) in Company
26th Jan 20262:38 pmRNSHolding(s) in Company
26th Jan 202610:48 amRNSHolding(s) in Company
23rd Jan 20264:49 pmRNSHolding(s) in Company
23rd Jan 20262:58 pmRNSHolding(s) in Company
22nd Jan 20264:16 pmRNSHolding(s) in Company
22nd Jan 20263:16 pmRNSHolding(s) in Company
21st Jan 20262:56 pmRNSHolding(s) in Company
16th Jan 202612:17 pmRNSHolding(s) in Company
15th Jan 20263:43 pmRNSHolding(s) in Company
14th Jan 20264:59 pmRNSHolding(s) in Company
9th Jan 20267:00 amRNSPortfolio Valuation and NTA Update
22nd Dec 20253:01 pmRNSHolding(s) in Company
22nd Dec 20253:01 pmRNSHolding(s) in Company
16th Dec 20255:19 pmRNSHolding(s) in Company
3rd Dec 20257:00 amRNSAppointment of Non-Executive Director
1st Dec 202510:17 amRNSHolding(s) in Company
26th Nov 20254:34 pmRNSHolding(s) in Company
24th Nov 20253:58 pmRNSResult of Meeting
20th Nov 202510:12 amRNSHolding(s) in Company
19th Nov 202510:07 amRNSHolding(s) in Company
13th Nov 20253:02 pmRNSHolding(s) in Company
6th Nov 20255:19 pmRNSHolding(s) in Company
5th Nov 20259:43 amRNSHolding(s) in Company
4th Nov 20257:00 amRNSPublication of Circular & Notice of GM
20th Oct 20255:03 pmRNSHolding(s) in Company
20th Oct 20253:53 pmRNSHolding(s) in Company
17th Oct 20253:58 pmRNSHolding(s) in Company
16th Oct 20253:36 pmRNSHolding(s) in Company
10th Oct 20253:13 pmRNSForm 8.3 - Life Science REIT plc
3rd Oct 20255:59 pmRNSHolding(s) in Company
23rd Sep 20253:17 pmRNSForm 8.3 - Life Science REIT plc
23rd Sep 20257:00 amRNSHalf Year Results
22nd Sep 20253:22 pmRNSForm 8.3 - Life Science REIT plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.